BioSpace News Archive

Biotech Bay

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease.

September 5, 2022
·
9 min read
Biotimize Announces the Opening of a Fundraising Round to Build the First Biological CDMO in Brazil

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, announced the opening of a $30 million Series A fundraising round.

September 5, 2022
·
2 min read
Lunit to Showcase 5 Abstracts at ESMO 2022

Lunit announced the presentation of five abstracts highlighting the effectiveness of its AI-biomarker platform - Lunit SCOPE - at the European Society of Medical Oncology Congress 2022, held in Paris from September 9 to 13.

September 5, 2022
·
2 min read
Drug Development

Recruitment opens for Phase II trial in prostate cancer with Cu-64 SAR-Bombesin in the US

Clarity Pharmaceuticals is pleased to announce that the US-based diagnostic 64Cu SAR-Bombesin trial for patients with PSMA-negative prostate cancer is open for recruitment.

September 5, 2022
·
8 min read
Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal announced positive topline results from the first pivotal study of sunvozertinib in platinum-pretreated NSCLC Patients with EGFR exon20ins mutations at the European Society for Medical Oncology Annual Meeting.

September 5, 2022
·
5 min read
Biotech Bay

Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer

Bristol Myers Squibb announced the presentation of scientific research across several solid tumors showcasing the breadth of the Company’s oncology development program at the European Society for Medical Oncology Congress 2022 from September 9-13 in Paris, France.

September 5, 2022
·
62 min read
Deals

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

Clarus Therapeutics Holdings, Inc. announced that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.

September 5, 2022
·
6 min read
Onera Launches Innovative Sleep Diagnostics Solution in Europe

Onera Health, a leader in transforming sleep medicine and remote monitoring, announced the official launch of its ground-breaking solution to diagnose sleep disorders in Europe.

September 5, 2022
·
3 min read
Policy

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech announced that Alvotech received communication from the U.S. Food and Drug Administration detailing its assessment of the March 2022 inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland and Alvotech’s subsequent written responses to the FDA.

September 5, 2022
·
7 min read
Business

CellOrigin Biotech announced strategic global collaboration with Qilu Pharmaceutical to develop “off-the-shelf” CAR-iMAC cell therapy

CellOrigin Biotech Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary “off-the-shelf” iPSC-derived Chimeric Antigen Receptor Macrophages for cancer immnotherapy.

September 5, 2022
·
2 min read